
    
      Trial to assess the efficacy of Lenvatinib in metastatic neuroendocrine tumor. The primary
      endpoint of the study is overall response rate (ORR) by RECIST v 1.1 upon central radiologic
      assessment.

      Number of patients: 110 patients Estimated duration of subject participation: 24 months
    
  